Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MYB | P10242 | 14/20 | 0.70 |
| ▸ | GAA | P10253 | 2/20 | 0.62 |
| ▸ | MAPT | P10636 | 2/20 | 0.62 |
| ▸ | MEN1 | O00255 | 1/20 | 0.62 |
| ▸ | LMNA | P02545 | 1/20 | 0.62 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.62 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.62 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.61 |
| ▸ | MPO | P05164 | 1/20 | 0.61 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.60 |
| ▸ | RAB9A | P51151 | 1/20 | 0.60 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.60 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8544234 | 0.89 | MYB (0.75) | MYBGAAMAPTMEN1LMNA | |
| SCHEMBL8112346 | 0.87 | MPO (0.56) | MYBGAAMAPTMEN1LMNA | |
| SCHEMBL8538269 | 0.85 | MYB (0.76) | MYBGAAMAPTMEN1LMNA | |
| SCHEMBL8541180 | 0.85 | MPO (0.59) | MYBGAAMAPTMEN1LMNA | |
| SCHEMBL31237908 | 0.85 | MYB (0.83) | MYBGAAMAPTMEN1LMNA | |
| SCHEMBL8537195 | 0.84 | MYB (0.67) | MYBGAAMAPTMEN1LMNA | |
| SCHEMBL8112962 | 0.83 | KDM4E (0.74) | MYBGAAMAPTMEN1LMNA | |
| SCHEMBL8539602 | 0.83 | MYB (0.71) | MYBGAAMAPTMEN1LMNA | |
| SCHEMBL8544035 | 0.83 | MYB (0.73) | MYBGAAMAPTMEN1LMNA | |
| SCHEMBL8539407 | 0.83 | MYB (0.58) | MYBMPO |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9376725-B1 | Methods of screening for compounds for treating muscular dystrophy using human ALPHA7 integrin mRNA translation regulation | PTC THERAPEUTICS, INC. (US) | 2016-06-28 | — | — | US | claimed |
| US-8741572-B1 | Methods of screening for compounds for treating muscular dystrophy using mIGF1 mRNA translation regulation | PTC THERAPEUTICS, INC. (US) | 2014-06-03 | — | — | US | claimed |
| US-8283115-B1 | Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation | PTC THERAPEUTICS, INC. (US) | 2012-10-09 | — | — | US | claimed |
| US-9376725-B1 | Methods of screening for compounds for treating muscular dystrophy using human ALPHA7 integrin mRNA translation regulation | PTC THERAPEUTICS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376725-B1 | Methods of screening for compounds for treating muscular dystrophy using human ALPHA7 integrin mRNA translation regulation | PTC THERAPEUTICS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-9376725-B1 | Methods of screening for compounds for treating muscular dystrophy using human ALPHA7 integrin mRNA translation regulation | PTC THERAPEUTICS, INC. (US) | 2016-06-28 | — | — | US | disclosed |
| US-8741572-B1 | Methods of screening for compounds for treating muscular dystrophy using mIGF1 mRNA translation regulation | PTC THERAPEUTICS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741572-B1 | Methods of screening for compounds for treating muscular dystrophy using mIGF1 mRNA translation regulation | PTC THERAPEUTICS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8741572-B1 | Methods of screening for compounds for treating muscular dystrophy using mIGF1 mRNA translation regulation | PTC THERAPEUTICS, INC. (US) | 2014-06-03 | — | — | US | disclosed |
| US-8283115-B1 | Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation | PTC THERAPEUTICS, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283115-B1 | Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation | PTC THERAPEUTICS, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| US-8283115-B1 | Methods of screening for compounds for treating muscular dystrophy using UTRN mRNA translation regulation | PTC THERAPEUTICS, INC. (US) | 2012-10-09 | — | — | US | disclosed |
| EP-0537949-B1 | Antiproliferative derivatives of 4H-naphtho 1,2-b pyran | LILLY CO ELI (GB) | 1998-07-01 | — | — | EP | disclosed |
| US-5284868-A | Naphthopyran derivatives; for autoimmune diseases, cancer | ELI LILLY AND COMPANY (US) | 1994-02-08 | — | — | US | disclosed |
| US-5281619-A | Administering naphtho(1,2-B)pyran derivatives | ELI LILLY AND COMPANY (US) | 1994-01-25 | — | — | US | disclosed |
| EP-0537949-A1 | Antiproliferative derivatives of 4H-naphtho 1,2-b pyran | LILLY INDUSTRIES LIMITED (GB) | 1993-04-21 | — | — | EP | disclosed |